News    Matrix-Bio Options Metabolite Biomarker Technology from Purdue University to Evaluate Opportunities for New Cancer Diagnostic Tests

Matrix-Bio Options Metabolite Biomarker Technology from Purdue University to Evaluate Opportunities for New Cancer Diagnostic Tests

Posted June 5, 2013 by Matrix-Bio • No Comments


FORT WAYNE, IND., June 5, 2013 – Matrix-Bio Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive agreement with the Purdue Research Foundation optioning metabolite biomarker technology and eight patent applications to evaluate the commercial potential of cancer diagnostics tests based on the technologies.

Download PDF


No Comments

No comments yet.

Sorry, the comment form is closed at this time.


CONNECT WITH MATRIX-BIO

If you have questions about Matrix-Bio’s early liver cancer detection test or about our investing and partnership opportunities, please contact:

Eric Beier, MD, MBA
ebeier@matrix-bio.com